Virpax Pharmaceuticals Inc Total Liabilities
Virpax Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Virpax Pharmaceuticals Inc (VRPX) has total liabilities worth $2.47 Million USD as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Virpax Pharmaceuticals Inc (VRPX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Virpax Pharmaceuticals Inc (2018–2024)
Total liabilities of Virpax Pharmaceuticals Inc from 2018 to 2024. This chart illustrates how Virpax Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Virpax Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Virpax Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Portmeirion Group PLC
LSE:PMP
|
UK | GBX48.98 Million |
|
Sino-German United AG
F:SGU
|
Germany | €1.03 Million |
|
PCI Biotech Holding ASA
OL:PCIB
|
Norway | Nkr6.01 Million |
|
Abingdon Health Plc
LSE:ABDX
|
UK | GBX4.25 Million |
|
HARVEST MINERALS LTD
F:7HM
|
Germany | €4.89 Million |
|
Baltic Bridge S.A.
WAR:WIS
|
Poland | zł6.36 Million |
|
Digital 9 Infrastructure PLC
LSE:DGI9
|
UK | GBX3.23 Million |
|
C3is Inc.
NASDAQ:CISS
|
USA | $3.39 Million |
Liability Composition Analysis (2018–2024)
This chart breaks down Virpax Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Virpax Pharmaceuticals Inc (VRPX) total assets.
Liquidity & Leverage Metrics
Virpax Pharmaceuticals Inc Total Liabilities Ratios Explained
Virpax Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.70 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Virpax Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Virpax Pharmaceuticals Inc (2018–2024)
The table below shows the annual total liabilities of Virpax Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.47 Billion | +31994.70% |
| 2023-12-31 | $7.69 Million | +148.63% |
| 2022-12-31 | $3.09 Million | +48.23% |
| 2021-12-31 | $2.09 Million | -55.41% |
| 2020-12-31 | $4.68 Million | +68.46% |
| 2019-12-31 | $2.78 Million | +121.57% |
| 2018-12-31 | $1.25 Million | -- |
About Virpax Pharmaceuticals Inc
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an … Read more